secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001701541-24-000028
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Q2 2024 net loss $19.9M; cash runway into Q4 2025; Phase 2 data on track
--------------------------------------------------------------------------------

- Cash, equivalents, investments $123.0M at June 30, 2024, down from $131.4M at Dec 31, 2023; runway into Q4 2025.
- Net loss $19.9M in Q2 2024 vs $19.2M in Q2 2023; R&D expenses decreased to $12.6M from $13.2M.
- Initial Phase 2 data for BDTX-1535 in 2L/3L EGFRm NSCLC on track for later Q3 2024; 1L data in Q1 2025.
- Initial Phase 1 data for BDTX-4933 in KRASm NSCLC on track for Q4 2024; ESMO poster in September 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000170154124000028/0001701541-24-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000170154124000028/bdtx-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001701541-24-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer